Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8GH7

142D6 bound to BIR3-XIAP

Summary for 8GH7
Entry DOI10.2210/pdb8gh7/pdb
Related PRD IDPRD_002528
DescriptorE3 ubiquitin-protein ligase XIAP, BIR3 inhibitor MAA-CHG-PRO-ZHW, ZINC ION, ... (5 entities in total)
Functional Keywordsbir domain, protein-ligand complex, bir3 inhibitor, zinc finger motif, signaling protein, signaling protein-inhibitor complex, signaling protein/inhibitor
Biological sourceHomo sapiens (human)
More
Total number of polymer chains4
Total formula weight24596.31
Authors
Garza-Granados, A.,McGuire, J.,Baggio, C.,Pellecchia, M.,Pegan, S.D. (deposition date: 2023-03-09, release date: 2023-07-05, Last modification date: 2023-07-12)
Primary citationUdompholkul, P.,Garza-Granados, A.,Alboreggia, G.,Baggio, C.,McGuire, J.,Pegan, S.D.,Pellecchia, M.
Characterization of a Potent and Orally Bioavailable Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist.
J.Med.Chem., 66:8159-8169, 2023
Cited by
PubMed Abstract: We have recently reported on the use of aryl-fluorosulfates in designing water- and plasma-stable agents that covalently target Lys, Tyr, or His residues in the BIR3 domain of the inhibitor of the apoptosis protein (IAP) family. Here, we report further structural, cellular, and pharmacological characterizations of this agent, including the high-resolution structure of the complex between the Lys-covalent agent and its target, the BIR3 domain of X-linked IAP (XIAP). We also compared the cellular efficacy of the agent in two-dimensional (2D) and three-dimensional (3D) cell cultures, side by side with the clinical candidate reversible IAP inhibitor LCL161. Finally, pharmacokinetic studies indicated that the agent was long-lived and orally bioavailable. Collectively our data further corroborate that aryl-fluorosulfates, when incorporated correctly in a ligand, can result in Lys-covalent agents with pharmacodynamic and pharmacokinetic properties that warrant their use in the design of pharmacological probes or even therapeutics.
PubMed: 37262387
DOI: 10.1021/acs.jmedchem.3c00467
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.75 Å)
Structure validation

239492

数据于2025-07-30公开中

PDB statisticsPDBj update infoContact PDBjnumon